12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zoptarelin doxorubicin acetate: SPA received

On Dec. 28, 2012, Aeterna said it reached an agreement with FDA on an SPA for an open-label, international Phase III trial to compare AEZS-108 vs. doxorubicin in about 500 patients. The...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >